Shows & Panels
- The 2014 Big Picture on Cyber Security
- AFCEA Answers
- Ask the CIO
- Building the Hybrid Cloud
- Connected Government: How to Build and Procure Network Services for the Future
- Continuing Diagnostics and Mitigation: Discussion of Progress and Next Steps
- Federal Executive Forum
- Federal Tech Talk
- The Future of Government Data Centers
- The Future of IT: How CIOs Can Enable the Service-Oriented Enterprise
- The Intersection: Where Technology Meets Transformation
- Maximizing ROI Through Data Center Consolidation
- Modern Mission Critical Series
- Moving to the Cloud. What's the best approach for me
- Navigating Tough Choices in Government Cloud Computing
- The New Generation of Database
- Satellite Communications: Acquiring SATCOM in Tight Times
- Targeting Advanced Threats: Proven Methods from Detection through Remediation
- Transformative Technology: Desktop Virtualization in Government
- The Truth About IT Opex and Software Defined Networking
- Value of Health IT
- Air Traffic Management Transformation Report
- Cloud First Report
- General Dynamics IT Enterprise Center
- Gov Cloud Minute
- Government in Technology Series
- Homeland Security Cybersecurity Market Report
- National Cybersecurity Awareness Month
- Technology Insights
- The Cyber Security Report
- The Next Generation Cyber Security Experts
Shows & Panels
Pfizer: Once-a-day Lyrica failed in epilepsy trial
Friday - 11/16/2012, 11:26am EST
NEW YORK (AP) - Pfizer says that a long-lasting version of its anti-seizure drug Lyrica failed to significantly decrease epilepsy symptoms when compared with placebo.
The company said Friday that a study of two doses of once-a-day pregabalin CR showed the pills were well tolerated, but did not meet the study's goal of decreasing seizure frequency. The company tracked patients' seizures for 28 days while taking the drug and compared that rate to an 8-week baseline period.
Pfizer said it will continue with two other studies evaluating the drug for fibromyalgia and post-herpetic neuralgia.
Lyrica is Pfizer's top-selling drug with sales of $1.04 billion in the most recent quarter. The regular formulation of the drug is approved to prevent seizures and pain associated with diabetes, shingles and fibromyalgia.
Pfizer Inc. shares rose a penny to $23.67 in midday trading.
(Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)